HOME > TRENDS

    TRENDS

    Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground

    By Reiji Anasako July 16, 2019
    Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…

    To read the full story

    Related Article

    TRENDS

    COLUMN

    The Pros and Cons of Working from Home in 2022
    By Philip Carrigan

    As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

    COMMENTARY

    Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
    By Yoshinori Sagehashi

    Debates on the planned FY2023 off-year drug price revision are now entering the final stretch. Healthcare providers and payers have made their conflicting positions clear on the scope of products to be covered by the re-pricing, while the pharma industry…

    Chuikyo on Off-Year Drug Price Revision

    Chuikyo Reps Tussle over Product Coverage Threshold for Off-Year Price Revision

    A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…

    MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals

    Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers

    Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…